Synergistic Effect of Cytochrome P450 Family 3 Subfamily A Member 5 (<i>CYP3A5)</i> Genetic Variants in Tacrolimus Dose Determination in Indian Renal Transplant Patients-Reference-Cited by-同舟云学术

Synergistic Effect of Cytochrome P450 Family 3 Subfamily A Member 5 (CYP3A5) Genetic Variants in Tacrolimus Dose Determination in Indian Renal Transplant Patients

Published:2024-08-13 Issue: Volume: Page:
ISSN:2575-9108
Container-title:ACS Pharmacology & Translational Science
language:en
Short-container-title:ACS Pharmacol. Transl. Sci.

Author:

Hemani Rashmi J.¹²,Chauhan Priyal M.²,Srivastava Ratika³^ORCID,Shete Nitiraj B.⁴,Jojera Amit S.¹,Soni Shailesh M.¹,Gang Sishir D.⁵,Konnur Abhijit M.⁵,Hegde Umapati N.⁵,Patel Hardik B.⁵,Mukhopadhyay Banibrata N.¹,Raval Manan A.⁶,Pandey Sachchida Nand¹^ORCID

Affiliation:

1. Department of Pathology, Muljibhai Patel Urological Hospital, Dr. V. V. Desai Road, Nadiad 387001, Gujarat, India

2. Department of Pharmacology, Ramanbhai Patel College of Pharmacy, Charotar University of Science and Technology (CHARUSAT), CHARUSAT Campus, Changa 388421, Gujarat, India

3. School of Life Sciences, Department of Biotechnology, Babasaheb Bhimrao Ambedkar University (A Central University), Lucknow 226025, Uttar Pradesh, India

4. Department of Biostatistics, Muljibhai Patel Urological Hospital, Nadiad 387001, Gujarat, India

5. Department of Nephrology, Muljibhai Patel Urological Hospital, Nadiad 387001, Gujarat, India

6. Department of Pharmacognosy, Ramanbhai Patel College of Pharmacy, Charotar University of Science and Technology (CHARUSAT), CHARUSAT Campus, Changa 388421, Gujarat, India

Funder

Indian Council of Medical Research

Charotar University of Science and Technology

Muljibhai Patel Urological Hospital

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acsptsci.4c00055

Reference38 articles.

1. Pharmacogenetics of tacrolimus: ready for clinical translation?

2. Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report

3. Dosing algorithm for Tacrolimus in Tunisian Kidney transplant patients: Effect of CYP 3A4*1B and CYP3A4*22 polymorphisms

4. Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs

5. In Vivo CYP3A4 Activity, CYP3A5 Genotype, and Hematocrit Predict Tacrolimus Dose Requirements and Clearance in Renal Transplant Patients